ストックスクリーナーアプリを入手
0.99
3.88%
-0.04
アフターアワーズ：
.98
-0.01
-1.01%
前日終値:
$1.03
開ける：
$1.03
24時間の取引高:
120.70K
Relative Volume:
1.89
時価総額：
$35.46M
収益：
-
当期純損益:
$-8.53M
株価収益率:
-4.0674
EPS:
-0.2434
ネットキャッシュフロー:
$-12.75M
1週間 パフォーマンス:
-25.00%
1か月 パフォーマンス:
-10.00%
6か月 パフォーマンス:
-10.00%
1年 パフォーマンス:
-7.04%
1日の値動き範囲:
$0.97
$1.03
1週間の範囲:
$0.89
$1.35
52週間の値動き範囲:
$0.63
$3.23
Estrella Immunopharma Inc Stock (ESLA) Company Profile
名前
Estrella Immunopharma Inc
セクター
電話
(510) 318-9098
住所
5858 HORTON STREET, SUITE 370, EMERYVILLE
ESLA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
0.99 | 35.46M | 0 | -8.53M | -12.75M | -0.2434 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Estrella Immunopharma Inc (ESLA) 最新ニュース
Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Yahoo Finance
Sector Update: Health Care -February 21, 2025 at 03:42 pm EST - Marketscreener.com
Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - The Bakersfield Californian
Can This New Cancer Therapy Revolutionize NHL Treatment? Early Trial Results Show Promise - StockTitan
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital - Business Wire
Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital - Defense World
Can This Revolutionary T-Cell Platform Transform Blood Cancer Treatment? Analysts Think So - StockTitan
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Estrella Immunopharma regains Nasdaq compliance - Investing.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Estrella Immunopharma extends stock sale agreement with White Lion By Investing.com - Investing.com Canada
Estrella Immunopharma faces Nasdaq delisting over equity shortfall - Investing.com
Chengxi Shipyard Co., Ltd. announced that it expects to receive CNY 425 million in funding from China Structural Reform Fund Co., Ltd., China Pacific Property Insurance Co., Ltd., China Life Insurance Company Limited, PICC Property and Casualty Company - Marketscreener.com
Estrella Immunopharma Inc (ESLA) Quarterly 10-Q Report - Quartzy
Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St
Eureka Therapeutics Tackling Advanced Hepatocellular Carcinoma With T-Cell Therapy ECT204 in Phase 1/2 ARYA-3 Clinical Trial - CGTLive™
Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks
Decoding Houlihan Lokey Inc (HLI): A Strategic SWOT Insight - Yahoo Finance Australia
Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com UK
ARMOUR Residential REIT, Inc. Announces November 2024 Dividend Rate per Common Share - Yahoo Finance Australia
Westrock Coffee Company (WEST) Moves 10.8% Higher: Will This Strength Last? - Yahoo Finance Australia
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive™
HP Inc. gets hit with downgrade from Citigroup - Yahoo Finance Australia
Estrella Immunopharma Inc (ESLA) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Stocks to Watch: Wynn Resorts, Estrella Immunopharma, Amazon.com - MarketWatch
Stocks to Watch : Wynn Resorts, Estrella Immunopharma, Amazon.com - Marketscreener.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Estrella Immunopharma Shares Rise on Lymphoma Patient's Treatment Response - MarketWatch
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS - Business Wire
Best Income Stocks to Buy for September 25th - Yahoo Finance Australia
EXTR INVESTOR UPDATE: Suffer Losses on Your Extreme Networks, Inc. Investment? Contact BFA Law by October 15 about Pending Class Action Lawsuit (Nasdaq:EXTR) - ForexTV.com
Arizona State Retirement System Has $78,000 Stock Holdings in Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) - Defense World
Shareholders that lost money on Extreme Networks, Inc. (EXTR) Urged to Join Class Action – Contact The Gross Law Firm to Learn More - ForexTV.com
Elutia Inc. (NASDAQ:ELUT) Sees Large Decrease in Short Interest - Defense World
Kessler Topaz Meltzer & Check, LLP Reminds Investors of - GlobeNewswire
Extra Storage rises on Jefferies upgrade - XM
Debt-Free Multibagger Stock Hit 18 Consecutive Upper Circuits & 52-Week Highs: Will the Rally Come to a Halt? - Dalal Street Investment Journal
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Extreme Networks, Inc.EXTR - PR Newswire
Extreme Networks (EXTR) Tumbled 18% After Guiding For - GlobeNewswire
Clene (NASDAQ:CLNN) Stock Quotes, Forecast and News Summary - Benzinga
The Psychology of Extreme Networks Inc. Inc. (EXTR) Price Performance: Understanding Market Sentiment - The InvestChronicle
Despite selling recently, Dell Technologies Inc. (NYSE:DELL) insiders own 50% stake and recent decline might have cost them - Yahoo Finance Australia
Here is What to Know Beyond Why PayPal Holdings, Inc. (PYPL) is a Trending Stock - Yahoo Finance Australia
Uptake of Nononcology Gene Therapy Remains Slow in Hematology - CGTLive™
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - Business Wire
Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas Doses First Patient - CGTLive™
ESLA’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Estrella Immunopharma Inc (ESLA) 財務データ
収益
当期純利益
現金流量
EPS
6.45%
1.23%
大文字化:
|
ボリューム (24 時間):